Ionis Pharmaceuticals (IONS) Operating Expenses (2009 - 2026)

Ionis Pharmaceuticals' Operating Expenses history runs 18 years deep, the most recent figure standing at $370.2 million for Q2 2026.

• In Q2 2026, Operating Expenses rose 18.58% year-over-year to $370.2 million; the TTM figure through Jun 2026 stood at $1.5 billion (up 21.3% YoY), while the FY2025 annual figure was $1.3 billion, up 12.3% from the prior year.
• Operating Expenses for Q2 2026 stood at $370.2 million, up from $363.5 million in the prior quarter.
• The five-year high for Operating Expenses was $417.8 million in Q4 2025, with the low at $199.4 million in Q1 2022.
• The 5-year median for Operating Expenses is $289.4 million (2023), against an average of $298.8 million.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses soared 64.04% in 2022, then fell 8.14% in 2023.
• Ionis Pharmaceuticals' Operating Expenses stood at $359.9 million in 2022, then declined by 8.14% to $330.6 million in 2023, then gained by 2.05% to $337.4 million in 2024, then gained by 23.83% to $417.8 million in 2025, then fell by 11.38% to $370.2 million in 2026.
• Business Quant data shows IONS's Operating Expenses at $370.2 million in Q2 2026, $363.5 million in Q1 2026, and $417.8 million in Q4 2025.